Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. (r)-n-(3-quinuclidinyl)-7-oxo-dihydrothieno(3,2b)pyridine-6-carboxamide Hydrochloride
2. Dpp-733
3. Mkc-733
1. Pumosetrag [inn]
2. 153062-94-3
3. Chembl1643880
4. 1g26b32139
5. N-((3r)-1-azabicyclo(2.2.2)oct-3-yl)-7-oxo-4,7-dihydrothieno(3,2-b)pyridine-6-carboxamide
6. Ddp 733
7. Unii-1g26b32139
8. Schembl390615
9. Ddp733
10. Zinc16869
11. Dtxsid70165211
12. Bdbm50334438
13. Db12402
14. 1055328-70-5
15. Q27252379
16. (r)-7-oxo-n-(quinuclidin-3-yl)-4,7-dihydrothieno[3,2-b]pyridine-6-carboxamide
17. N-[(3r)-1-azabicyclo[2.2.2]octane-3-yl]-7-oxo-4,7-dihydrothieno[3,2-b]pyridine-6-carboxamide
18. Thieno(3,2-b)pyridine-6-carboxamide, N-(3r)-1-azabicyclo(2.2.2)oct-3-yl-4,7-dihydro-7-oxo-
19. Thieno(3,2-b)pyridine-6-carboxamide, N-1-azabicyclo(2.2.2)oct-3-yl-4,7-dihydro-7-oxo-, (r)-
| Molecular Weight | 303.4 g/mol |
|---|---|
| Molecular Formula | C15H17N3O2S |
| XLogP3 | 1.7 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 2 |
| Exact Mass | 303.10414797 g/mol |
| Monoisotopic Mass | 303.10414797 g/mol |
| Topological Polar Surface Area | 89.7 Ų |
| Heavy Atom Count | 21 |
| Formal Charge | 0 |
| Complexity | 499 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in constipation, gastroesophageal reflux disease (GERD), gastrointestinal diseases and disorders (miscellaneous), and irritable bowel syndrome (IBS).
DDP733 is an agonist of 5-HT3 receptors, a specific sub-type of serotonin receptor. Serotonin, a neurotransmitter, is believed to play an important role in the regulation of gastrointestinal motility.
ABOUT THIS PAGE
41
PharmaCompass offers a list of Pumosetrag API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Pumosetrag manufacturer or Pumosetrag supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Pumosetrag manufacturer or Pumosetrag supplier.
PharmaCompass also assists you with knowing the Pumosetrag API Price utilized in the formulation of products. Pumosetrag API Price is not always fixed or binding as the Pumosetrag Price is obtained through a variety of data sources. The Pumosetrag Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Pumosetrag manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Pumosetrag, including repackagers and relabelers. The FDA regulates Pumosetrag manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Pumosetrag API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Pumosetrag supplier is an individual or a company that provides Pumosetrag active pharmaceutical ingredient (API) or Pumosetrag finished formulations upon request. The Pumosetrag suppliers may include Pumosetrag API manufacturers, exporters, distributors and traders.
Pumosetrag Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Pumosetrag GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Pumosetrag GMP manufacturer or Pumosetrag GMP API supplier for your needs.
A Pumosetrag CoA (Certificate of Analysis) is a formal document that attests to Pumosetrag's compliance with Pumosetrag specifications and serves as a tool for batch-level quality control.
Pumosetrag CoA mostly includes findings from lab analyses of a specific batch. For each Pumosetrag CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Pumosetrag may be tested according to a variety of international standards, such as European Pharmacopoeia (Pumosetrag EP), Pumosetrag JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Pumosetrag USP).
